Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio IM034-1014  |   NCT06248814

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Resumen

  • Phase 1
  • Ícono de género masculino y femenino
  • 18-75
  • 10
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

The purpose of this study is to assess the safety, tolerability, drug levels, drug effects, and impact on disease severity of BMS-986326 in participants with moderate-to-severe atopic dermatitis (AD).

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Inclusion Criteria: - Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening - Documented history of inadequate response to treatment with topical medication for at least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has required systemic therapy for control of disease - All the following must be present to confirm moderate-to-severe AD - Eczema Area and Severity Index score ≥ 12 (at Screening and Day 1) - Body Surface Area ≥ 10% (at Screening and Day 1) - Validated Investigator Global Assessment for Atopic Dermatitis ≥ 3 (at Screening and Day 1) - Peak Pruritus Numerical Rating Scale ≥ 4 (at Screening) Exclusion Criteria: - Evidence of an active and/or concurrent inflammatory skin condition that would interfere with the Investigator or subject-driven evaluations of AD - Any major surgery within the last 30 days before the first dose of study intervention, or any surgery planned during the course of the study - Any other sound medical, psychiatric, and/or social reason as determined by the investigator Other protocol-defined inclusion/exclusion criteria apply

Opciones de tratamiento

Brazos del estudio

INTERVENCIÓN ASIGNADA

Brazos del estudio

Experimental: BMS-986326 Dose A, followed by Placebo

INTERVENCIÓN ASIGNADA

Brazos del estudio

Experimental: BMS-986326 Dose B, followed by Placebo

INTERVENCIÓN ASIGNADA

Brazos del estudio

Experimental: Placebo, followed by BMS-986326 Dose A or Dose B

INTERVENCIÓN ASIGNADA
Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
Verifique su elegibilidad
Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
Compatibilizar con un estudio
Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
Seleccione una ubicación del centro del estudio
Seleccione una ubicación del centro del estudio que sea conveniente para usted
Registrarse
Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias